Romaniuk V. M.

DENTISTRY

Scentific article

Modern diagnosis of periimplant and periodontal diseases is based on clinical and radiological studies, which for decades are commonly used by all specialists in oral protection, and they are easy and practical to interpret. However, clinicians can detect and measure periimplant / periodontal disease only after clinical manifestations have occurred using traditional methods. Key biomarkers of peri-implant and periodontal tissue destruction, once detected, can alert the clinician to the onset of collagen breakdown long before clinical manifestations. Preliminary studies support the concept of matrix metalloproteinase-8 (MMP-8), also known as neutrophil collagenase or collagenase-2, as a potential key biomarker responsible for connective tissue destruction or active degeneration of periodontal and peri-implant tissues. MMP-8 is a major collagenolytic proteinase and is thought to be responsible for the irreversible destruction of periodontal and periimplant tissues. The aim of the study was to evaluate the dynamics of markers of bone metabolism in the oral fluid of patients with chronic generalized periodontitis of varying severity. The research was conducted on the basis of NNMC «University Clinic» ZSMU. 80 patients aged 18 to 65 years were examined. Among them, 20 healthy patients were the control group and 60 the main with periodontal disease and dentition defects. In patients with stage I-III chronic periodontitis, a statistically significant increase in the concentration of bone tissue markers MMP8 and soluble kappa nucleation factor activator (sRANKL) ligand was observed compared to the control group. It is important to note that the dynamics of their content correlated with the severity of the disease. Thus, in patients of group 1, the concentration of MMP8 and sRANKL decreased by an average of 49% and 53%; 2 groups – by 78% and 64% according to the control group. In patients of group 3, divergent dynamics of the content of the studied markers was recorded. Thus, the concentration of MMP8 was 0.47 [0.1; 0.77] and correlated with the stage of the disease and changes in clinical parameters index PI, index PMA, index OHI-S. At the same time, the concentration of sRANKL was 0.28 [0.09 0.37], which is on average lower than in patients of groups 1 and 2. In patients of all clinical groups on the background of treatment, there was a decrease in the concentration of MMP8 on the background of increasing the content of sRANKL. Such changes, in our opinion, indicated a decrease in the intensity of osteodestruction processes against the background of increased osteosynthesis, which to some extent testified to the effectiveness of treatment of generalized periodontitis in patients 1-3 groups.In combination with a set of clinical and radiological research methods and other biochemical indicators involved in bone formation and resorption, MMP8 and sRANKL should be used to monitor changes in bone tissue in the treatment of patients with chronic periodontitis. The disclosure of the regulatory role of MMP8 and sRANKL in osteoclastogenesis of bone tissue justifies the creation of highly effective ways of pharmacological correction of chronic periodontitis by agonist antagonists of these protein molecules.

chronic periodontitis, bone destruction, matrix metalloproteinase, sRANKL.

1. Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nature Reviews Microbiology. 2010;8(7):481-490.
2. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. The Lancet. 2005;366(9499):1809-1820.
3. Slots J. Periodontology: past, present, perspectives. Periodontol 2000. 2013;62(1):7-19.
4. Durham J, Fraser HM, McCracken GI, Stone KM, John MT, Preshaw PM. Impact of periodontitis on oral health-related quality of life. Journal of Dentistry. 2013;41(4):370-376.
5. Elani HW, Starr JR, Da Silva JD, Gallucci GO. Trends in dental implant use in the U.S., 1999-2016, and projections to 2026. Journal of Dental Research. 2018;97:1424-1430.
6. Pjetursson BE, Thoma D, Jung R, Zwahlen M, Zembic A. A systematic review of the survival and complication rates of implant-supported fixed dental prostheses (FDPs) after a mean observation period of at least 5 years. Clinical Oral Implants Research. 2012;23:22-38.
7. Manor Y, Oubaid S, Mardinger O, Chaushu G, Nissan J. Characteristics of early versus late implant failure: A retrospective study. Journal of Oral and Maxillofacial Surgery. 2009;(67):2649-2652.
8. Schwarz F, Derks J, Monje A, Wang HL. Peri-implantitis. Journal of Clinical Periodontology. 2018;45:246-266.
9. Derks J, Tomasi C. Peri-implant health and disease. A systematic review of current epidemiology. Journal of Clinical Periodontology. 2015;42:158-171.
10. Heitz-Mayfield L, Salvi GE. Peri-implant mucositis. Journal of Clinical Periodontology. 2018;45:237-245.
11. Alassy H, Parachuru P, Wolff L. Peri-implantitis diagnosis and prognosis using biomarkers in peri-implant crevicular fluid: A narrative review. Diagnostics (Basel). 2019:9:214.
12. Arias-Bujanda N, Regueira-Iglesias A, Balsa-Castro C, Nibali L, Donos N, Tomás I. Accuracy of single molecular biomarkers in gingival crevicular fluid for the diagnosis of periodontitis: A systematic review and meta-analysis. Journal of Clinical Periodontology. 2019;46:1166- 1182.
13. Carinci F, Romanos GE, Scapoli L. Molecular tools for preventing and improving diagnosis of peri-implant diseases. Periodontology. 2019;81:41-47.
14. Gul SS, Abdulkareem AA, Sha AM, Rawlinson A. Diagnostic Accuracy of oral fluids biomarker profile to determine the current and future status of periodontal and peri-implant diseases. Diagnostics (Basel). 2020;10:838.
15. Al-Majid A, Alassiri S, Rathnayake N, Tervahartiala T, Gieselmann DR, Sorsa T. Matrix metalloproteinase-8 as an Inflammatory and prevention biomarker in periodontal and peri-implant diseases. International Journal of Dentistry. 2018;78:913-23.
16. Sorsa T, Tjäderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, et al. Matrix metalloproteinases: Contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Annals of Medicine. 2006;38:306-321.
17. Buduneli N. Biomarkers in Periodontal Health and Disease. Switzerland: Springer; 2020. 90 p.
18. Dejonckheere E, Vandenbroucke RE, Libert C. Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression. Cytokine and Growth Factor Reviews. 2011;22:73-81.
19. Luo W, Chen W, Lung WY, Wei XY, Cheng BH, Cai ZM, et al. EGCG Inhibited Bladder Cancer SW780 Cell Proliferation and Migration Both in Vitro and in Vivo via Down-Regulation of NF-ΚB and MMP-9. J. Nutr. Biochem. 2017;41:56-64. DOI: 10.1016/j.jnutbio.2016.12.004.
20. Ramseier CA, Kinney JS, Herr AE, Braun T, Sugai JV, Shelburne CA, et al. Identification of Pathogen and Host-Response Markers Correlated with Periodontal Disease. J. Periodontol. 2009;80:436-446. DOI: 10.1902/jop.2009. 080480.
21. Sapna G, Gokul S, Bagri-Manjrekar K. Matrix Metalloproteinases and Periodontal Diseases. Oral Dis. 2014;20:538-550. DOI: 10.1111/ odi.12159.
22. Sorsa T, Alassiri S, Grigoriadis A, Räisänen IT, Pärnänen P, Nwhator SO, et al. Active MMP-8 (AMMP-8) as a Grading and Staging Biomarker in the Periodontitis Classification. Diagnostics. 2020;10:61. DOI: 10.3390/diagnostics 10020061.
23. Charles K, Honibald E, Reddy N, Palani A, Ramamurthy R, Sankaralingam T. Role of Matrix Metalloproteinases (MMPS) in Periodontitis and Its Management.MJ. Indian Acad. Dent. Spec. Res. 2014;1:65-69.
24. Yakob M, Meurman JH, Sorsa T, Söder B. Treponema Denticola Associates with Increased Levels of MMP-8 and MMP-9 in Gingival Crevicular Fluid. Oral Dis. 2013;19:694-701. DOI: 10.1111/odi.12057.
25. Luizon MR, De Almeida Belo V. Matrix Metalloproteinase (MMP)-2 and MMP-9 Polymorphisms and Haplotypes as Disease Biomarkers. Biomarkers. 2012;17:286-288. DOI: 10.3109/1354750X.2012.657685.
26. Javed F, Ahmed HB, Mikami T, Almas K, Romanos GE, AlHezaimi K. Cytokine profile in the gingival crevicular fluid of rheumatoid arthritis patients with chronic periodontitis. J. Invest. Clin. Dent. 2014;5(1):1-8. DOI: 10.1111/jicd. 12066.

«Bulletin of problems biology and medicine» Issue 2 Part 2 (165), 2022 year, 231-241 pages, index UDK 616.314.17-008.1-031.81-06:616.314-001/-007]-07:577.112

10.29254/2077-4214-2022-2-2-165-231-241